Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCX · Real-Time Price · USD
7.29
+0.21 (2.97%)
At close: May 23, 2025, 4:00 PM
7.30
+0.01 (0.14%)
After-hours: May 23, 2025, 5:34 PM EDT
Medicus Pharma Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Medicus Pharma stock ranges from a low of $20 to a high of $27. The average analyst price target of $23.5 forecasts a 222.36% increase in the stock price over the next year.
Price Target: $23.50 (+222.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Medicus Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +270.37% | May 22, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 → $27 | Strong Buy | Maintains | $14 → $27 | +270.37% | May 12, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $10 → $20 | Strong Buy | Maintains | $10 → $20 | +174.35% | May 8, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +92.04% | Apr 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +92.04% | Apr 21, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|
| High | -2.58 | -0.96 | -0.58 | ||
| Avg | -2.51 | -1.22 | -0.77 | ||
| Low | -2.41 | -1.34 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.